WO1989003672A1 - Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying - Google Patents

Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying Download PDF

Info

Publication number
WO1989003672A1
WO1989003672A1 PCT/FR1988/000512 FR8800512W WO8903672A1 WO 1989003672 A1 WO1989003672 A1 WO 1989003672A1 FR 8800512 W FR8800512 W FR 8800512W WO 8903672 A1 WO8903672 A1 WO 8903672A1
Authority
WO
WIPO (PCT)
Prior art keywords
spraying
administered
nasal
precise
amphotericin
Prior art date
Application number
PCT/FR1988/000512
Other languages
French (fr)
Inventor
Louis Lefevre-Utile
Xavier Labayle
Nicole Tenaillon
Original Assignee
Medipro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipro filed Critical Medipro
Publication of WO1989003672A1 publication Critical patent/WO1989003672A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
  • Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase health expenditure by increasing the length of hospital stay.
  • the present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and oropharyngeal cavities.
  • the three antibiotics associated in the preparation are polymyxin B, netilmicin and amphotericin B.
  • the preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum spreading on the mucous membranes nasal and oropharyngeal.
  • the preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump.
  • Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and the vaporization of the nasal passages, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity .
  • valves or pumps will be very precise. They are of course a function of the concentration of antibiotics within the preparation.
  • the frequency of applications also depends on the concentration of these products.
  • valve or pump must be adapted to deliver 0.5 ml each time it is pressed.
  • 400 mg of polymyxin B, 360 mg of netilmicin and 2000 mg of amphotericin B are administered daily.

Abstract

The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, netilmycin and amphotericin B, administered by precise spraying in the nasal and oropharyngeal cavities either in the form of a pressurized aerosol dispensed by a continuous or dosing valve or in the form of a nasal spray dispensed by a precise pump. Two pushers are provided with each bottle: one having a long thin cannula for introduction into the nostrils and spraying of the nasal fossae, the other having a cannula permetting generous spraying of the oropharyngeal cavity. The drug has a wide range of indications in all patients at risk of contracting a gram-negative bacillary infection or a mycosis.

Description

Médicament comprenant l'association de polymyxine B, de nétilmicine et d'amphotéricine B administré par vaporisation. Medicine comprising the combination of polymyxin B, netilmicin and amphotericin B administered by vaporization.
La présente invention concerne un médicament pour vaporisation destiné à prévenir les risques d'infection chez les malades à risques en décontami- nant les cavités nasales et oropharyngées.The present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
Les infections à bacilles gram négatif et les mycoses sont fréquentes chez les malades à risques. Elles entraînent une morbidité importante, elles sont une des causes principales du décès de ces patients, elles aug¬ mentent les dépenses de santé en augmentant les durées d'hospitalisation. La présente invention permet de remédier à cet inconvénient. Elle com¬ porte l'association de trois antibiotiques administrée par vaporisation dans les cavités nasales et oropharyngées. Les trois antibiotiques asso¬ ciés dans la préparation sont la polymyxine B, la nétilmicine et l'ampho- téricine B. La préparation doit adhérer aux muqueuses nasales et buccales, relarguer lentement les antibiotiques et avoir une tension superficielle permettant un étalement maximal sur le muqueuses nasales et oropharyngées. La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise. Deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fos¬ ses nasales,l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée.Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase health expenditure by increasing the length of hospital stay. The present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and oropharyngeal cavities. The three antibiotics associated in the preparation are polymyxin B, netilmicin and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum spreading on the mucous membranes nasal and oropharyngeal. The preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump. Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and the vaporization of the nasal passages, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity .
Les doses distribuées par les valves ou les pompes seront très précises. Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation.The doses distributed by the valves or pumps will be very precise. They are of course a function of the concentration of antibiotics within the preparation.
La fréquence des applications dépend également de la concentration de ces produits.The frequency of applications also depends on the concentration of these products.
Aucun de ces antibiotiques n'étant absorbé par voie nasale, oropharyn- gée ou digestive, les posologies et donc les concentrations peuvent varier dans une très large part.None of these antibiotics being absorbed by the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
Les caractéristiques et avantages de l'invention ressortent de la des¬ cription qui va suivre à titre d'exemple : pour 30 ml de préparation on associe : - sulfate de polymyxine B : 500 mgThe characteristics and advantages of the invention appear from the description which will follow by way of example: for 30 ml of preparation, the following are combined: - polymyxin sulfate B: 500 mg
FEUILLE DE REMPLACEMENT - sulfate de nétilmicine 450 mgREPLACEMENT SHEET - netilmicin sulfate 450 mg
- amphotéricine B 2500 mg- amphotericin B 2500 mg
- alcool à 90° 1 ml- 90 ° alcohol 1 ml
- saccharinate de sodium 100 mg- sodium saccharinate 100 mg
- essence de menthe 0,02 ml- mint essence 0.02 ml
- glycérine quantité suffisante pour- glycerin sufficient amount to
30 ml La valve ou la pompe doit être adaptée pour délivrer 0,5 ml à chaque pression. On recommande 6 pressions dans la cavités oropharyngée, 3 pres- sions dans chaque narine à chaque administration et une fréquence de qua¬ tre administrations par jour. Dans cet exemple, on administre 400 mg de polymyxine B, 360 mg de nétilmicine et 2000 mg d'amphotéricine B par jour.30 ml The valve or pump must be adapted to deliver 0.5 ml each time it is pressed. We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril at each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin B, 360 mg of netilmicin and 2000 mg of amphotericin B are administered daily.
Il est recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par sonde gastrique avec ces mêmes antibiotiques.It is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by gastric tube with these same antibiotics.
Les indications de ce médicament sont très larges : il doit être emplo¬ yé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent : en réanimation, en hématologie, en chirurgie, en anesthesiologie, en cancérologie, etc.. The indications for this drug are very broad: it should be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc. .

Claims

REVENDICATIONS
1) Médicament destiné à prévenir les risques d'infections à bacilles gram négatif caractérisé en ce qu'il comporte l'association de trois anti- giotiques : polymyxine B, nétilmicine. et amphotéricine B administrée par vaporisation dans les cavités nasales et oropharyngées.1) Medication intended to prevent the risks of infections with gram-negative bacilli, characterized in that it comprises the combination of three antibiotics: polymyxin B, netilmicin. and amphotericin B administered by spraying into the nasal and oropharyngeal cavities.
2) Médicament selon la revendication 1 caractérisé en ce que la prépa¬ ration est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise.2) Medicament according to claim 1 characterized in that the prepa¬ ration is administered by precise spraying either in the form of pressurized aerosol dispensed by a continuous valve or metering or in the form of nebulization dispensed by a precise pump.
3) Médicament selon la revendication 1 ou la revendication 2 caractéri¬ sé en ce que les doses distribuées par les valves ou les pompes sont très précises.3) Medicament according to claim 1 or claim 2 caractéri¬ se in that the doses dispensed by the valves or pumps are very precise.
4) Médicament selon l'une quelconque des revendications précédentes caractérisé en ce que deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines, l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée. 4) Medicament according to any one of the preceding claims, characterized in that two pushers are supplied with each bottle: one having a long and fine cannula allowing the introduction through the nostrils, the other of a cannula allowing wide vaporization of the oropharyngeal cavity.
PCT/FR1988/000512 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying WO1989003672A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR87/14346 1987-10-19
FR8714346A FR2621818B1 (en) 1987-10-19 1987-10-19 MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION

Publications (1)

Publication Number Publication Date
WO1989003672A1 true WO1989003672A1 (en) 1989-05-05

Family

ID=9355911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1988/000512 WO1989003672A1 (en) 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying

Country Status (3)

Country Link
AU (1) AU2624888A (en)
FR (1) FR2621818B1 (en)
WO (1) WO1989003672A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014849A1 (en) * 1994-11-11 1996-05-23 HAIDER, Angelika Use of aminoglycosides to diagnose blood-air barrier disorders
RU2605263C1 (en) * 2015-11-05 2016-12-20 государственное автономное научное учреждение "Институт стратегических исследований Республики Башкортостан" Ointment with netilmicin and propolis extract for integrated treating inflammatory periodontal diseases
US9545487B2 (en) 2012-04-13 2017-01-17 Boehringer Ingelheim International Gmbh Dispenser with encoding means
US9682202B2 (en) 2009-05-18 2017-06-20 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US9724482B2 (en) 2009-11-25 2017-08-08 Boehringer Ingelheim International Gmbh Nebulizer
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
US9757750B2 (en) 2011-04-01 2017-09-12 Boehringer Ingelheim International Gmbh Medicinal device with container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
US10004857B2 (en) 2013-08-09 2018-06-26 Boehringer Ingelheim International Gmbh Nebulizer
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US10099022B2 (en) 2014-05-07 2018-10-16 Boehringer Ingelheim International Gmbh Nebulizer
US10124129B2 (en) 2008-01-02 2018-11-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
US10124125B2 (en) 2009-11-25 2018-11-13 Boehringer Ingelheim International Gmbh Nebulizer
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL121455C (en) * 1900-01-01
GB1018125A (en) * 1962-11-29 1966-01-26 Merck & Co Inc Chemical products
AU539563B2 (en) * 1981-01-21 1984-10-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Primycin, doxycyline and sisomicin composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL121455C (en) * 1900-01-01
GB1018125A (en) * 1962-11-29 1966-01-26 Merck & Co Inc Chemical products
AU539563B2 (en) * 1981-01-21 1984-10-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Primycin, doxycyline and sisomicin composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Merck Index, 10ième édition, 1983, Merck & Co. (Rahway, N.J. US), voir nos. 611, 6322, 7445 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014849A1 (en) * 1994-11-11 1996-05-23 HAIDER, Angelika Use of aminoglycosides to diagnose blood-air barrier disorders
US10124129B2 (en) 2008-01-02 2018-11-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US9682202B2 (en) 2009-05-18 2017-06-20 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US9724482B2 (en) 2009-11-25 2017-08-08 Boehringer Ingelheim International Gmbh Nebulizer
US10124125B2 (en) 2009-11-25 2018-11-13 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
US9757750B2 (en) 2011-04-01 2017-09-12 Boehringer Ingelheim International Gmbh Medicinal device with container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US10220163B2 (en) 2012-04-13 2019-03-05 Boehringer Ingelheim International Gmbh Nebuliser with coding means
US9545487B2 (en) 2012-04-13 2017-01-17 Boehringer Ingelheim International Gmbh Dispenser with encoding means
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
US10004857B2 (en) 2013-08-09 2018-06-26 Boehringer Ingelheim International Gmbh Nebulizer
US10894134B2 (en) 2013-08-09 2021-01-19 Boehringer Ingelheim International Gmbh Nebulizer
US11642476B2 (en) 2013-08-09 2023-05-09 Boehringer Ingelheim International Gmbh Nebulizer
US10716905B2 (en) 2014-02-23 2020-07-21 Boehringer Lngelheim International Gmbh Container, nebulizer and use
US10099022B2 (en) 2014-05-07 2018-10-16 Boehringer Ingelheim International Gmbh Nebulizer
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
RU2605263C1 (en) * 2015-11-05 2016-12-20 государственное автономное научное учреждение "Институт стратегических исследований Республики Башкортостан" Ointment with netilmicin and propolis extract for integrated treating inflammatory periodontal diseases

Also Published As

Publication number Publication date
FR2621818A1 (en) 1989-04-21
AU2624888A (en) 1989-05-23
FR2621818B1 (en) 1990-12-14

Similar Documents

Publication Publication Date Title
WO1989003672A1 (en) Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying
WO1989003673A1 (en) Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying
EP0390832A1 (en) Medicinal preparation comprising the association of colistin, tobramycin and amphotericin b administered by atomization
ES2330415T3 (en) SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS.
WO2005046640A3 (en) Multi-site drug delivery platform
CA2039456A1 (en) Osmotic dosage system for liquid drug delivery
PT984762E (en) DEBIT CONTROLLER CONFIGURATIONS FOR AN ACTIVE AGENT ADMINISTRATION DEVICE
DK0998916T3 (en) Medicines for administration to the mucosa
ES2104522T3 (en) NEW MEDICINAL ADMINISTRATION SYSTEM.
WO2003009883B1 (en) Catheter for modification of agent formulation
MX170801B (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF SEXUALLY COMMUNICABLE DISEASES
WO2004039351A3 (en) Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
US4876283A (en) Antisnoring agent
WO2002007810A3 (en) Catheter for target specific drug delivery
CA2141026A1 (en) Pharmaceutical Compositions for Transmucosal Delivery of Peptides
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
CA1223210A (en) Antisnoring agent
BE900749A (en) MICROENCAPSULE DRUG IN A SWEET MATRIX.
WO2003032946A3 (en) Ph-sensitive liposomes for targeted drug delivery
CA2296231C (en) Composition and method for treating common viral infections
FR2624017A1 (en) Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation
FR2622113A1 (en) Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation
FR2624739A1 (en) Medicament comprising a combination of colistin, neomycin and amphotericin B administered by vaporisation
JP2004506678A5 (en)
FR2624738A1 (en) Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BG BR DK FI HU JP NO RO SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG